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Rapamycin-sensitive phosphorylation of PKC on a carboxy-
terminal site by an atypical PKC complex
W.H. Ziegler*†, D.B. Parekh*, J.A. Le Good*, R.D.H. Whelan*, J.J. Kelly*,
M. Frech‡, B.A. Hemmings‡ and P.J. Parker*
Background: The protein kinase C (PKC) family has been implicated in the
control of many cellular functions. Although PKC isotypes are characterized by
their allosteric activation, phosphorylation also plays a key role in controlling
activity. In classical PKC isotypes, one of the three critical sites is a carboxy-
terminal hydrophobic site also conserved in other AGC kinase subfamily
members. Although this site is crucial to the control of this class of enzymes,
the upstream kinase(s) has not been identified. 
Results: A membrane-associated kinase activity that phosphorylates the
hydrophobic site in PKCα was detected. This activity was suppressed when
cells were pretreated with the immunosuppresant drug rapamycin or the
phosphoinositide (PI) 3-kinase inhibitor LY294002. These pretreatments also
blocked specifically the serum-induced phosphorylation of the hydrophobic site
in PKCδ in vivo. The most highly purified hydrophobic site kinase preparations
(~10,000-fold) reacted with antibodies to PKCζ/ι. Consistent with this,
rapamycin and LY294002 reduced the recovery of PKCζ from the membrane
fraction of transfected cells. An activated mutant of PKCζ, but not wild-type
PKCζ, induced phosphorylation of the PKCδ hydrophobic site in a rapamycin-
independent manner, whereas a kinase-dead PKCζ mutant suppressed this
serum-induced phosphorylation. The immunopurified, activated mutant of PKCζ
could phosphorylate the PKCδ hydrophobic site in vitro, whereas wild-type
PKCζ could not. 
Conclusions: PKCζ is identified as a component of the upstream kinase
responsible for the phosphorylation of the PKCδ hydrophobic site in vitro and in
vivo. PKCζ can therefore control the phosphorylation of this PKCδ site,
antagonizing a rapamycin-sensitive pathway.
Background
Classical and novel protein kinase C (PKC) isotypes are
direct targets for the second messenger diacylglycerol
[1–3]. Allosteric activation by diacylglygcerol, together
with the activation by the phorbol ester class of tumour
promoters, has contributed to the view that PKC isotypes
are involved in many signalling responses in cells. Recent
studies have defined a further level of regulation involving
phosphorylation. The cPKC isotypes have been shown to
be phosphorylated on at least three sites in vivo including
a conserved carboxy-terminal hydrophobic site
Phe–X–X–Phe–Ser/Thr–Tyr/Phe (where X is any amino
acid) [4–6]. In the PKCα protein this hydrophobic site
(containing Ser657) has been shown to be rate-limiting for
the accumulation of the active (latent), fully phosphory-
lated kinase [6]. A number of related members of the
AGC subfamily of protein kinases (where AGC represents
cyclic AMP-dependent protein kinase, cyclic GMP-
dependent protein kinase and protein kinase C family)
[7] have been shown to be phosphorylated at a similar
hydrophobic site carboxy-terminal to their kinase
domains. Notably, although certain related proteins
including PKCζ and PKCι retain the hydrophobic motif,
they have an acidic residue in place of the serine/threo-
nine residue [8,9]. In addition to the carboxy-terminal
hydrophobic site, a number of AGC kinases have phos-
phorylation sites in their activation loops that are also con-
served in PKC isotypes. An activation loop kinase, 3′
phosphoinositide-dependent protein kinase (PDK1), has
been identified for protein kinase B [10,11] and was
recently shown to act also upon p70 S6 kinase (p70)
[12,13] as well as PKCδ and PKCζ [14,15]. PDK1 does not
phosphorylate the hydrophobic carboxy-terminal site,
however, and to date the enzyme that is responsible for
the phosphorylation of this motif has not been found. In
p70, phosphorylation of this hydrophobic site is critical for
the activity of p70 and it is also the site most sensitive to
the potent immunosuppressant drug rapamycin [16]. Elu-
cidation of the rapamycin-dependent signalling pathway
that controls p70, and that operates on other AGC kinase
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subfamily proteins, requires the identification of the prox-
imal protein kinase activity. Here we show that phospho-
rylation of this hydrophobic site in PKCδ is a
rapamycin-sensitive process and identify the atypical PKC
isotype PKCζ as a component of the kinase responsible
for this phosphorylation of PKCδ.
Results
In PKC isotypes, the hydrophobic phosphorylation site is
located in the carboxy-terminal variable 5 domain (V5
domain). To identify a V5 kinase activity in vitro, a V5
domain fragment of PKCα (as a glutathione-S-transferase
fusion termed GST–V5α) was used as a substrate to screen
fractionated cell extracts. The specificity of phosphorylation
was monitored by use of antisera selective for the phospho-
rylated Ser657 residue (Ser657(P)) site, as well as use of
mutant proteins containing serine/threonine to alanine
mutations at either the Thr638 or Ser657 phosphorylation
sites (T638A or S657A, respectively), or at both sites. It is
evident that the kinase activity has some selectivity for the
Ser657 site and that the Ser657-phosphorylated protein
migrates more slowly than the substrate does (Figure 1a). A
membrane-associated activity was identified in all cells
types investigated (COS-7, U937, HeLa and Jurkat) as well
as in rat brain tissue. In each case the activities displayed
similar elution properties on anion exchange chromatogra-
phy (for example, Figure 1b). On the basis of 32P-orthophos-
phate incorporation into the slower migrating GST–V5α
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Figure 1
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Identification of a Ser657 V5 kinase activity. (a) Phosphorylation-site
specificities of V5α kinase fractions were tested in vitro using
GST–V5α constructs. GST–V5α contains two of the characterized in
vivo PKCα phosphorylation sites, Thr638 and Ser657. The
corresponding alanine substitution-mutants of GST–V5α,
GST–V5α(T638A) and GST–V5α(S657A), confirm the site specificity
of kinase fractions. GST–V5α(T638A) is phosphorylated like the wild-
type protein (WT), while GST–V5α(S657A) and the double mutant
GST–V5α(T638A,S657A), represented by AA in the figure, are not
significantly phosphorylated. The Ser657(P)-specific bands on the
immunoblot (black arrow, upper panel) correspond to 32P signals on
the autoradiograph (black arrow, lower panel). The background
immunoreactivity (arrowhead) does not alter in any of the mutants; this
corresponds to the bulk of the unphosphorylated substrate, coinciding
with the position of the Coomassie-blue-stained protein (data not
shown). (b) MonoQ elution profile of a COS-7 cell membrane extract
(the first chromatographic step of kinase purification). The eluted V5
kinase activity is shown; no activity is detected in the unbound fraction
(data not shown). The autoradiograph (inset) shows the 32P
incorporation into GST–V5α by the eluted fractions, the arrow
indicating the Ser657-phosphorylated GST–V5α and the arrowhead
indicating the Ser657-nonphosphorylated protein. The asterisk
indicates a non-specific phosphoprotein that is present at this first step
of purification. (c) Bacterially expressed, full-length PKCδ is
phosphorylated by the V5α kinase preparation on the Ser662 site as
shown by the phosphorylation-site-specific antiserum (the specificity of
this antiserum is illustrated in Figure 3). This bacterially expressed
GST–PKCδ is autophosphorylated on Ser643 as isolated. On
incubation in vitro, it will further autophosphorylate on an undefined
site but not on Ser662. The V5 kinase phosphorylates Ser662.
Phorbol myristate acetate (PMA) is an allosteric activator of PKCδ.
domain and the immunodetection with the Ser657(P)-spe-
cific antibody, this membrane-derived activity was further
purified by sequential chromatography on MonoQ, MonoS
and MiniQ columns (see Materials and methods section).
Although the purification yielded an overall enrichment of
around 10,000-fold relative to the crude extract, the protein
was not pure as judged by Coomassie blue staining follow-
ing polyacrylamide gel electrophoresis (this estimation of
the enrichment is a minimum estimate because there are
likely to be contaminating kinase activities at the earlier
steps in the purification). 
To investigate the specificity of this highly purified
activity, PKCδ was tested as a substrate. Unphosphory-
lated PKCδ was purified as a GST-fusion protein from
bacteria. This recombinant protein has a low basal activ-
ity (~20 units/mg), is phosphorylated at Ser643 [17] (cor-
responding to the Thr638 site in PKCα) and
autophosphorylates in vitro, but not on either of the sites
Thr505 [14] or Thr662 (Figure 1c). Only in the presence
of the V5 kinase does GST–PKCδ become phosphory-
lated at the carboxy-terminal hydrophobic site Ser662, as
evidenced by immunoreaction with the site-specific anti-
body (Figure 1c). These results indicate that this V5
kinase preparation appears to have non-exclusive sub-
strate specificity in vitro, because it phosphorylates the
equivalent sites on both PKCα (V5 domain) and PKCδ
(intact protein).
Phosphorylation of the homologous hydrophobic site
(Thr389) of p70 is sensitive to treatment of cells with
rapamycin and phosphoinositide (PI) 3-kinase inhibitors,
such as LY294002 ([18] and references therein). This prece-
dent suggested that the V5 kinase activity itself might be
sensitive to these inhibitors. Isolation of membranes from
U937 cells pretreated with such inhibitors revealed that V5
kinase activity was substantially reduced compared with
control cells that had not been pretreated with inhibitors
(Figure 2). An assessment of PKC phosphorylation sensitiv-
ity to rapamycin has not been carried out previously. To
determine the sensitivity of PKCδ phosphorylation at the
Ser662 site in vivo, 293 cells were transfected with a
plasmid containing PKCδ and were serum-starved. Phos-
phorylation of Ser662 was monitored with a site-specific
antiserum that showed selective recognition of the phos-
phorylated Ser662 site and specific competition by the
phosphopeptide antigen (Figure 3a,b). Under these serum-
starved conditions a decrease in Ser662 PKCδ phosphoryla-
tion was observed (Figure 3b). Stimulation of starved cells
with 10% serum induced the phosphorylation of Ser662
(Figure 3c). In the presence of rapamycin or LY294002,
however, there was an inhibition of serum-induced Ser662
phosphorylation (Figure 3c,d). PKCδ, like p70 [16], there-
fore displays a rapamycin sensitivity in vivo, suggesting that
aspects of the responses of cells to rapamycin treatment
might be mediated through alteration in PKCδ function.
To identify the kinase responsible and reconstitute the
phosphorylation, direct protein sequence analysis of the
V5 kinase preparation was performed. Mass spectrometry
of tryptic fragments from the highly purified protein
revealed that the major protein staining bands were het-
erogeneous and no known kinase or kinase-related
sequence was identified. Because the kinase was below
the levels of detection by sequence, we screened a
number of kinase candidates by immunological methods.
A commercial antibody (Santa Cruz) recognises both atyp-
ical PKC (aPKC) isotypes (ζ and ι) because it is specific
for a peptide corresponding to residues 573–592 of PKCζ,
which is almost entirely conserved in PKCι. This antibody
identified an 80 kDa protein and a predicted PKCζ/ι
kinase domain fragment in the most highly purified prepa-
rations. These immunoreactive bands were not coincident
with the major staining proteins (Figure 4a), consistent
with the fact that aPKC tryptic sequences were not identi-
fied. The related PKCα was not present in these prepara-
tions (data not shown). Consistent with the notion that
PKCζ might contribute to this activity, we analysed the
membrane-associated PKCζ in control untreated cells and
in cells treated with LY294002 or rapamycin. As observed
for the V5 kinase activity there was an inhibitor-depen-
dent reduction in the recovery of PKCζ (Figure 4b). 
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Figure 2
Loss of membrane-associated V5 kinase activity in response to
rapamycin and LY294002. U937 cells were pretreated for 20 min with
rapamycin (20 nM) or LY294002 (10 µM), or were left untreated
(control). V5 kinase activity was purified and assayed with GST–V5α
as substrate (see Materials and methods section). A representative
western blot of GST–V5α phosphorylation is shown in the upper
panel. The mean activities (± standard deviations) for three
independent experiments are indicated in the lower panel.
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These observations indicated that aPKC might be a compo-
nent of the PKC kinase, phosphorylating hydrophobic
carboxy-terminal sites. To test this in intact cells we used
PKCδ as a readout and examined the effects of an activated
mutant of PKCζ that has threonine to glutamic acid muta-
tions at the activation loop phosphorylation site (Thr410)
and at the predicted autophosphorylation site (Thr560) [14].
When PKCδ is coexpressed with this PKCζ T410E/T560E
mutant, PKCδ remained partially phosphorylated at the
Ser662 hydrophobic site despite serum deprivation
(Figure 5a). This effect was site specific as no equivalent
phosphorylation was seen for the PKCδ activation loop site
(Thr505). Upon stimulation with serum there was an
increase in PKCδ Ser662 phosphorylation and this response
is rapamycin insensitive (Figure 5a). Consistent with this
insensitivity, in the presence of PKCζ T410E/T560E, the
constitutive Ser662 phosphorylation was also not suppressed
in the presence of rapamycin or LY294002 (data not shown).
Despite the PKCζ T410E/T560E-dependent change in
rapamycin sensitivity of the PKCδ Ser662 phosphorylation,
serum-induced Thr505 phosphorylation remained sensitive
to  LY294002 (Figure 5a). To assess whether PKCζ might
act on the serum-induced pathway, we determined the
effect of a dominant-negative PKCζ mutant [19]. Coexpres-
sion of PKCδ with PKCζ (T410A) blocked the serum-
induced phosphorylation of PKCδ Ser662 (Figure 5b). 
These results suggest that PKCζ can specifically effect
PKCδ Ser662 phosphorylation and that the overexpression
of its activated form removes the rapamycin sensitivity of
both the basal and serum-induced responses. To further
assess whether PKCζ could be responsible for PKCδ
phosphorylation, immunoprecipitated PKCζ(T410E), was
incubated in vitro with bacterially expressed PKCδ. Under
these conditions the PKCδ Ser662 site was phosphory-
lated by the PKCζ(T410E) immunocomplex (Figure 5c).
When immunoprecipitated wild-type PKCζ was assessed
in the same assay it was unable to induce PKCδ phospho-
rylation at the Ser662 site, indicative of a requirement for
activation of PKCζ (data not shown).
Discussion
These results demonstrate that an aPKC isotype is at least
a component of a PKC V5 kinase, phosphorylating the
Phe–X–X–Phe–Ser–Tyr motif. The initial evidence for
this came from the isolation of a PKCα V5 kinase activity,
which was shown to contain an aPKC antigen in the most
highly purified preparations (~10,000-fold purification).
The demonstration that immunopurified activated PKCζ
phosphorylated PKCδ in vitro and promotes this phospho-
rylation upon coexpression in vivo confirms this assign-
ment. It is also shown that the phosphorylation of this
hydrophobic V5 domain site in PKCδ is controlled
through a rapamycin-sensitive pathway, a property that is
overcome by expression of the activated PKCζ mutant.
The ability of coexpressed PKCζ(T410E,T560E) to
increase the phosphorylation of the PKCδ Ser662 site in
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Figure 3
Phosphorylation of PKCδ Ser662 is
dependent on growth conditions and is
inhibited by LY294002 (10 µM) and
rapamycin (20 nM). (a) The specificity of the
‘FSY’-site-specific antiserum on Ser662
phosphorylation of PKCδ expressed in 293
cells cultured in the presence or absence of
10% foetal calf serum (FCS) is illustrated.
Immunoreactivity is specifically eliminated by
competition of antiserum with the
phosphopeptide antigen (0.5 µg/ml); the
dephosphopeptide (1 µg/ml) used in (b–d)
suppresses non-specific immunoreaction with
the dephosphorylated protein. (b) Ser662
phosphorylation (upper panel) of bacterially-
expressed GST–PKCδ (negative control) and
of PKCδ from serum-maintained 293 cells
(10% FCS, + FCS) and after 24 h serum
starvation (– FCS). The protein loading was
assessed using a PKCδ carboxyl-terminus-
specific antiserum (lower panel). (c) Ser662
phosphorylation of PKCδ (left panel) is
induced by FCS treatment of serum-starved
293 cells and is optimal by 30 min after serum
stimulation (no further increase is seen at
60 min; data not shown). The serum-induced
phosphorylation is markedly reduced in cells
pretreated for 30 min with LY294002 or
rapamycin (as indicated). The PKCδ protein
load is shown in the righthand panel.
(d) Ser662 phosphorylation of PKCδ was
determined following 30 min serum stimulation
in control and rapamycin- or LY294002-
pretreated cells and quantified as a function of
PKCδ protein. The results are from four
independent experiments (mean ± SD).
(c) PKCδ
PKCδ
FCS
FCS + rapamycin
FCS + LY294002
Current Biology  
Time (min) Time (min)
10 300 10 300
(d) 30 min
(a)
PKCδ
P
K
C
δ 
S
er
6
62
(P
)
(%
 c
on
tr
ol
)
GST–
PKCδ
Ser662(P)
Ser662(P)
Ser662(P)
FCS – –++
Phosphopeptide + ––+
(b)
Co
ntr
ol
29
3 
ce
lls
 +
 FC
S
29
3 
ce
lls
 –
 FC
S FC
S
FC
S 
+ 
Ra
pa
my
cin
FC
S 
+ 
LY
29
40
02
0
25
50
75
100
125
97
kDa
66
97
66
vivo is site specific because the PKCδ activation loop
Thr505 site is not affected by PKCζ(T410E,T560E)
expression. The activated PKCζ mutant is able to bypass
rapamycin sensitivity of PKCδ Ser662 phosphorylation,
indicating that expression does not simply induce an
autocrine serum-like response; PKCζ-transfected cells do
not condition their media with factors that stimulate
Ser662 phosphorylation (D.B.P., unpublished observa-
tions). Although it can be concluded that aPKC appears to
be a component of a V5 kinase, it should be noted that the
membrane-associated aPKC showing V5 kinase activity
appears to be part of a complex because the native protein
is not immunoprecipitated by an antibody that will deplete
uncomplexed native recombinant PKCζ (unpublished
observations). Thus, the V5 kinase activity is associated
with a particular form of PKCζ that is complexed and/or
modified. The importance of some activating step for
PKCζ is directly evidenced here by the differential behav-
iour of wild-type PKCζ and the activated PKCζ mutant.
Although the former has no effect on PKCδ phosphoryla-
tion in vivo or in vitro, the latter supports phosphorylation
in both situations.
The sensitivity of PKC phosphorylation to rapamycin has
not been addressed previously. Interestingly, it has been
reported that rapamycin can inhibit PKC-dependent stimu-
lation of sodium transport [20] and this was thought to be
due to the direct inhibition of PKC activity by rapamycin.
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Figure 4
The aPKC correlates with V5 kinase activity. (a) The most highly
purified sample of the V5 kinase preparation was subjected to
polyacrylamide gel electrophoresis and was stained with Coomassie
blue to detect protein (left panel). The same sample was
immunoblotted (right panel) with a PKCζ/ι antiserum (Santa Cruz) in
the absence or presence of competing antigen (competition). The
major immunoreactive bands are not coincident with the stained
proteins and migrate at 80 kDa (PKCζ/ι) and 45 kDa (PKCζ/ι).
Immunoreactivity is completely competed by the antigen. (b) A plasmid
encoding PKCζ was transfected into 293 cells. Membranes were
prepared from these transfected cells that had been pretreated with
rapamycin (20 nM) or LY294002 (10 µM) or left untreated (control) as
indicated. Protein was extracted and separated by SDS–PAGE and
immunoblotted for aPKC, here transfected PKCζ. The recovery of
PKCζ was quantified by scanning densitometry yielding recoveries of
62% (rapamycin) and 48% (LY294002) as shown in the graph. The
immunoblot shown is one of two similar independent experiments.
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Figure 5
PKCδ Ser662 phosphorylation is controlled by PKCζ. (a) Plasmids
encoding PKCδ and PKCζ(T410E/T560E) were transfected into 293
cells as shown. Cells were serum-starved and then restimulated with
10% FCS for 20 min after pretreatment with rapamycin (20 nM) or
LY294002 (10 µM) as indicated. Extracts were prepared and
immunoblotted for PKCδ phosphorylation (Ser662 and Thr505 sites)
and PKC expression as indicated. Expression of the PKCζ mutant
bypasses the sensitivity of Ser662 phosphorylation to the two
inhibitors; no significant effect is seen for the Thr505 site. (b) Plasmids
encoding PKCδ and PKCζ(T410A) were transfected into 293 cells as
shown. Starved cells were then stimulated with 10% FCS for 20 min
after pretreatment with rapamycin or LY294002 and extracts analysed
for PKCδ expression and Ser662 phosphorylation. The mutant PKCζ is
seen to inhibit the serum-induced PKCδ phosphorylation.
(c) Immunopurified PKCζ(T410E) was incubated with purified
GST–PKCδ and the phosphorylation of the PKCδ Ser662 site
monitored by immunoblotting. Only the immunocomplex containing
PKCζ(T410E) catalysed phosphorylation of PKCδ. In this figure Rap
denotes rapamycin and LY denotes LY294002.
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The results presented here, however, indicate that the inhi-
bition might occur upstream at the level of a rapamycin-
sensitive phosphorylation. Dephosphorylation of PKCδ by
serum starvation and rapamycin treatment dramatically
reduces its activity in in vitro kinase assays (D.B.P. and
P.J.P., unpublished observations). Thus, rapamycin influ-
ences the catalytic activity of PKCδ through the control of
Ser662 phosphorylation. A clear precedent exists in the
form of p70 which is well established as a downstream
target of rapamycin (and PI 3-kinase inhibitors) [21]. Like
PKC, p70 has a Phe–X–X–Phe–Ser/Thr–Tyr/Phe phospho-
rylation motif carboxy-terminal to the kinase domain, the
phosphorylation of which is known to be sensitive to
rapamycin [16]. The additional rapamycin-induced loss of
phosphorylation of p70 in the activation loop site [22] might
mirror the situation in PKCα in which we have established
that alanine mutations in either of the carboxy-terminal
sites (the autophosphorylation site Thr638 and the
hydrophobic site Ser657) sensitises the protein to dephos-
phorylation at the activation loop site [6,23]. It would seem
that these various AGC family kinases retain some similar
structural requirements for activity.
Previous studies in yeast and mammals have identified
members of the target of rapamycin (TOR) family as
targets of rapamycin ([24] and reviewed in [21]). Mam-
malian TOR (mTOR) is itself a member of the PI
3-kinase superfamily and is also sensitive to PI 3-kinase
inhibitors such as LY294002 [25]. The Ser657-specific V5
kinase/PKCζ is not inhibited directly by LY294002 (data
not shown) and PI 3-kinases are not sensitive to
rapamycin, hence our current understanding would
suggest that mTOR can control V5 domain phosphoryla-
tion on PKC. Whether or not this effect is principally
through control of aPKC or through control of a phos-
phatase activity is unresolved. The data here indicate a
reduced PKCζ/ι recovery in membrane preparations from
cells pretreated with rapamycin or LY294002, as observed
for the V5 kinase activity (see Results section). It seems
possible, however, that the inhibitory effect might be
channelled additionally through a protein phosphatase.
For the related phosphorylation of p70 and the rapamycin
-sensitive phosphorylation of eukaryote initiation factor
4E binding protein 1 (eIF-4E-BP1) there is evidence that
mTOR will phosphorylate relevant sites directly [26].
There is also evidence, however, that the rapamycin-sen-
sitive control of p70 is effected through a phosphatase
because an amino-terminal deletion in p70 converts the
kinase to a rapamycin-resistant form but does not affect its
phosphorylation in response to serum [27–29]. Whether
the kinases or phosphatases are dominant in controlling
these rapamycin-sensitive phosphorylations and those of
PKC awaits further analysis.
There are very few ‘in vivo’ substrates for aPKC isotypes
that are firmly established. The assignment of aPKCs as a
component of an upstream kinase for PKC is attractive,
given that aPKCs themselves escape an equivalent regu-
latory input to their carboxy-terminal hydrophobic region,
having a glutamic acid residue in place of serine/threo-
nine in the hydrophobic motif (Phe–X–X–Phe–Glu–Tyr).
This negatively charged residue can partially mimic
phosphorylation at this position, as evidenced by an
acidic mutation in PKCα [6]. The aPKC isotypes, in par-
ticular PKCζ, have been implicated in many cellular
functions but whether this is effected through their action
as PKC family (or even AGC superfamily) kinases
remains to be determined.
Conclusions
The evidence presented here demonstrates that PKCδ
phosphorylation at its conserved hydrophobic carboxy-ter-
minal site, Ser662, is under the control of a rapamycin-sen-
sitive pathway. The in vitro and in vivo studies presented
indicate that a component of the kinase activity responsi-
ble for this phosphorylation is an aPKC. Thus, aPKC
appears to act alongside PDK1 to control the phosphoryla-
tion of other PKC isotypes.
Materials and methods 
Expression and purification of recombinant proteins.
PKCα–V5 domain (D615–V672), wild-type and the alanine-substitu-
tion mutants T638A, S657A, AA (T638A,S657A), as well as PKCδ
(full-length) were cloned with a linker in pGex-2T (Pharmacia
Biotech) and expressed in Escherichia coli BL21 (DE3) cells
(Novagen). GST-fusion proteins were purified and eluted according
to the ‘GST Gene Fusion System’ manual (Pharmacia Biotech). The
dominant-negative PKCζ mutant (T410A) has been published [19]
and the activated mutants were obtained by site-directed mutagene-
sis of the Thr410 and Ser560 sites using conventional procedures
(J.A.L.G., unpublished observations). All mutant cDNAs were
sequenced to confirm integrity. 
Myc-tagged PKCζ (T410E) or wild-type Myc-tagged PKCζ were
expressed in 293 cells. Protein was immunopurified from extracts made
in 1% Triton X-100, 0.1 M NaCl, 50 mM Tris-HCl pH 7.5, 2 mM EDTA,
2 mM DTT, 1 µM microcystin, 10 µg/ml aprotinin, 10 µg/ml leupeptin,
0.5 mM phenylmethylsulphonylfluoride (PMSF), using affinity-purified
anti-Myc antibody and protein-G–agarose beads. Immunocomplexes
were washed twice with 1% Triton X-100, 0.2 M NaCl, 20 mM Tris-HCl
pH 7.5, 2 mM EDTA, 2 mM DTT, 1 µM microcystin, 10 µg/ml aprotinin,
10 µg/ml leupeptin, 0.5 mM PMSF and then once with an equivalent
buffer containing only 0.1 M NaCl and 0.05% Triton X-100. Immuno-
complexes were employed directly in kinase assays, with the equivalent
of one sixth of a 15 cm plate of transfected cells employed in each
phosphorylation reaction.
Purification of V5 kinase activity
Cells or rat brains were disrupted on ice in harvest buffer (20 mM Tris
pH 7.5, 10 mM EGTA, 5 mM EDTA, 1 mM DTT, 10 µg/ml leupeptin/
aprotinin, 10 mM benzamidine, 1 mM PMSF, 1µM microcystin) and
spun at low speed to clear extracts from debris and nuclei. Super-
natants were spun for 1 h at 100,000 × g. Pellets were resuspended in
harvest buffer, with 0.5 M NaCl added, and spun again for 1 h at
100,000 × g. Triton X-100 (1% (v/v) final) was added to supernatants,
which were then diluted 1:4 in buffer A (20 mM Tris (pH 7.5), 2 mM
EDTA, 10 mM benzamidine, 1 mM DTT, 0.02% Triton X-100) and
loaded onto a HiTrapQ column (5 ml) (FPLC-System, Pharmacia
Biotech). The protein was eluted in buffer A by application of a salt
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gradient (0–1 M NaCl). The V5 kinase activity was tested as described
below. The activity eluted in a single peak at 350–400 mM NaCl. The
active fractions were pooled and diluted 1:4 in buffer B (20 mM PIPES
(pH 6.5), with further components as buffer A). The protein fraction
was loaded onto a MonoS PC 1.6/5 column and the protein eluted in
buffer B using a salt gradient (0–1 M NaCl). The V5 kinase activity
eluted at 750–800 mM NaCl. The fractions were adjusted to pH 7.5,
diluted 1:5 in buffer A and loaded onto a MiniQ column (Smart-
System, Pharmacia Biotech). The V5 kinase activity was eluted at
350–400 mM salt (50 µl fractions).
The V5 kinase activity was assayed on GST–V5α protein substrate
(5 µg/reaction) bound to glutathione beads. Between 2.5 µl and 5.0 µl
of kinase fraction were added to the reaction mix (20 mM Tris pH 7.5,
10 mM MgCl2, 20µM ATP, 5 µCi [γ-32P]ATP in a final volume of 50 µl.
The samples were shaken for 20 min at 30°C. The beads were spun
down, the supernatant removed and the pellet washed twice in PBS
(with Triton X-100 (1%), 10 µg/ml aprotinin/leupeptin). The GST–V5α
substrate protein was eluted into SDS sample buffer and an aliquot
separated by SDS–PAGE. The protein was transferred onto nitrocellu-
lose and autoradiographed. The slow migrating, 32P-labelled GST–V5α
protein at 38 kDa, lines up exactly with the Ser657(P)-specific antibody
staining in the western analysis (see below) and was used to follow the
purification. The specific activity of the V5 kinase preparations was cal-
culated on basis of the specific 32P incorporation into the substrate.
The protein concentrations of the fractions were determined using the
Biorad protein assay (Biorad).
Western analysis
PKC isotypes were immunoblotted essentially as described previously
[30]. In addition, where stated, PKCζ/ι were detected with a commercial
antiserum to PKCζ (Santa Cruz) diluted 1:2,000 in the presence or
absence of peptide antigen (0.4 µg/ml) as indicated. The Ser657(P) site
specific polyclonal antiserum was raised against a phospho-peptide
‘FGFS[P]YVNP’, taken from the region flanking the FSY-motif in PKCα,
and tested against fully phosphorylated versus dephosphorylated PKCα
(D.B.P. and P.J.P., unpublished observations). The Thr505 antiserum
was as described previously [14]. Given that the Ser657(P) site specific
serum shows some cross-reactivity with the unphosphorylated
GST–V5α substrate protein, western analyses were always performed in
the presence of the cognate dephosphorylated peptide (dephosphopep-
tide) at 1 µg/ml. As shown in Figure 1a, the antiserum (dilution
1:1,000–1:4,000) clearly detects a slower migrating, phosphorylated
GST–V5α substrate band in the presence of dephosphopeptide. This
band matches exactly the 32P signal on the corresponding autoradi-
ograph and migrates slower than the Coomassie-blue-stainable
GST–V5α substrate bands (data not shown). Western blots were devel-
oped using horseradish peroxidase (HRP)-coupled donkey anti-rabbit
IgG secondary antiserum (Amersham; 1:5000) and ECL (Amersham).
Phosphorylation of PKCδ in vitro
For assays with the highly purified V5 kinase, eluted GST–PKCδ (1 µg
per reaction) was incubated for 2 h at 30°C with the kinase fraction
(2 µl) and PMA (0.5 µM) as indicated, in a reaction buffer (see kinase
assay above) containing 1 µM microcystin, 100 µM phosphatidyl-
choline, 100 µM phosphatidylserine. An aliquot of each reaction was
analysed using the PKCα FSY site specific antiserum (1:2,000). 
For phosphorylation with the immunopurifed PKCζ(T410E) mutant or
wild-type PKCζ, eluted GST–PKCδ was incubated for 60 min at 30°C
in a reaction buffer containing: 20 mM Tris-HCl pH 7.5, 10 mM MgCl2,
20 µM ATP, 100 nM TPA, 100 µM phosphatidylserine, 100 µM phos-
phatidylcholine, 1 µM microcystin. These experiments were carried out
additionally in the presence of the PKC inhibitor bisindolylmaleimide I,
which inhibits PKCδ but not aPKC isotypes except at considerably
higher concentrations (IC50, 5.8 µM [31]). Reactions were stopped by
addition of 10 mM (final) EDTA and Laemmli sample buffer. An aliquot
was subjected to immunoblotting to monitor PKCδ Ser662 phosphory-
lation as described above.
Inhibition of V5 kinase activity
U937 cells were grown in RPMI 1640 medium (10% FCS) to a density
of 4–5 × 105 cells/ml and cells were treated where indicated with
LY294002 (10 µM) or rapamycin (20 nM) for 20 min prior to protein
extraction. The V5 kinase preparation was performed as described in
the purification protocol. The salt extracts of the membrane pellets
were applied to analyze the V5 kinase activity (as described above).
The extent of specific GST–V5α substrate phosphorylation was deter-
mined based on the immunoreactivity signals (each experiment run in
duplicate) and normalized as a function of background immunoreactiv-
ity. The data are derived from three independent protein preparations.
Membrane-associated PKCζ in 293 cells
PKCζ in pEFlink was transfected into 293 cells [14]. Cells were
treated as indicated with rapamycin (20 nM) or LY294002 (10 µM) for
20 min prior to membrane preparation and protein extraction as
described in the purification of V5 kinase activity section. Equal
amounts of total protein were separated on SDS–PAGE and PKCζ
protein recovery analysed using a commercial antiserum to PKCζ
(Santa Cruz). 
PKCδ S662 phosphorylation in 293 cells
PKCδ was transfected into 293 cells [32] in pEFLink with or without
PKCζ (T410E,T560E or T410A) as indicated and starved for 24 h
before stimulation with 10% FCS for the indicated period of time.
Where present, LY294002 (10 µM) and rapamycin (20 nM) were
added to cells 30 min prior to stimulation. Whole cells were lysed in
SDS sample buffer and protein samples were separated by
SDS–PAGE. Protein was blotted and analysed for PKCδ Ser662 phos-
phorylation using the PKCα FSY-site specific antiserum (1:4000, with
dephosphopeptide 1 µg/ml), parallel samples were probed with a PKCδ
carboxy-terminus-specific antiserum [32]. In some instances, the
Thr505(P)-specific antiserum was employed to monitor phosphorylation
at the PKCδ Thr505 site. The extent of Ser662 phosphorylation was
determined based on the immunoreactivity signals and normalized as a
function of total PKCδ protein. The data are derived from four indepen-
dent experiments.
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